Victory Capital Management Inc. Has $309.30 Million Stake in Agilent Technologies, Inc. (NYSE:A)

Victory Capital Management Inc. raised its stake in Agilent Technologies, Inc. (NYSE:A) by 2.3% in the 2nd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 2,386,039 shares of the medical research company’s stock after purchasing an additional 52,550 shares during the quarter. Victory Capital Management Inc. owned 0.82% of Agilent Technologies worth $309,302,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other large investors also recently modified their holdings of A. Vanguard Group Inc. increased its stake in Agilent Technologies by 18.2% in the 1st quarter. Vanguard Group Inc. now owns 29,884,345 shares of the medical research company’s stock valued at $4,348,471,000 after buying an additional 4,605,228 shares during the last quarter. Norges Bank purchased a new stake in Agilent Technologies in the 4th quarter valued at about $509,904,000. Massachusetts Financial Services Co. MA increased its stake in shares of Agilent Technologies by 19.6% during the 4th quarter. Massachusetts Financial Services Co. MA now owns 13,246,489 shares of the medical research company’s stock worth $1,841,659,000 after purchasing an additional 2,170,219 shares during the last quarter. Brown Advisory Inc. increased its stake in shares of Agilent Technologies by 262.1% during the 4th quarter. Brown Advisory Inc. now owns 2,292,929 shares of the medical research company’s stock worth $318,786,000 after purchasing an additional 1,659,768 shares during the last quarter. Finally, Price T Rowe Associates Inc. MD increased its stake in shares of Agilent Technologies by 13.9% during the 1st quarter. Price T Rowe Associates Inc. MD now owns 8,542,054 shares of the medical research company’s stock worth $1,242,956,000 after purchasing an additional 1,042,926 shares during the last quarter. Institutional investors own 87.42% of the company’s stock.

Agilent Technologies Price Performance

A stock opened at $138.34 on Friday. The firm’s 50-day moving average price is $135.47 and its two-hundred day moving average price is $139.01. Agilent Technologies, Inc. has a 12-month low of $96.80 and a 12-month high of $155.35. The stock has a market capitalization of $40.36 billion, a price-to-earnings ratio of 32.70, a PEG ratio of 6.63 and a beta of 1.05. The company has a current ratio of 1.78, a quick ratio of 1.37 and a debt-to-equity ratio of 0.36.

Agilent Technologies (NYSE:A) last released its quarterly earnings data on Wednesday, August 21st. The medical research company reported $1.32 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.26 by $0.06. Agilent Technologies had a net margin of 21.75% and a return on equity of 25.26%. The firm had revenue of $1.58 billion for the quarter, compared to analysts’ expectations of $1.56 billion. During the same quarter in the previous year, the company earned $1.43 earnings per share. The company’s revenue for the quarter was down 5.6% compared to the same quarter last year. As a group, equities analysts predict that Agilent Technologies, Inc. will post 5.24 earnings per share for the current year.

Insider Activity

In other news, SVP Dominique Grau sold 15,000 shares of Agilent Technologies stock in a transaction dated Monday, June 10th. The shares were sold at an average price of $133.28, for a total transaction of $1,999,200.00. Following the sale, the senior vice president now owns 49,486 shares of the company’s stock, valued at approximately $6,595,494.08. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. In related news, CEO Padraig Mcdonnell sold 1,958 shares of the business’s stock in a transaction dated Thursday, August 22nd. The shares were sold at an average price of $145.00, for a total transaction of $283,910.00. Following the sale, the chief executive officer now owns 24,118 shares of the company’s stock, valued at $3,497,110. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, SVP Dominique Grau sold 15,000 shares of the business’s stock in a transaction dated Monday, June 10th. The stock was sold at an average price of $133.28, for a total transaction of $1,999,200.00. Following the sale, the senior vice president now directly owns 49,486 shares in the company, valued at approximately $6,595,494.08. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 18,916 shares of company stock valued at $2,557,230. Corporate insiders own 0.33% of the company’s stock.

Analyst Ratings Changes

Several research analysts recently commented on A shares. Bank of America raised their price objective on shares of Agilent Technologies from $140.00 to $147.00 and gave the stock a “neutral” rating in a report on Thursday, August 22nd. UBS Group raised their price target on shares of Agilent Technologies from $141.00 to $150.00 and gave the company a “neutral” rating in a report on Thursday, August 22nd. Evercore ISI raised their price target on shares of Agilent Technologies from $130.00 to $135.00 and gave the company an “in-line” rating in a report on Thursday, August 22nd. Wells Fargo & Company began coverage on shares of Agilent Technologies in a report on Tuesday, August 27th. They issued an “overweight” rating and a $157.00 price target for the company. Finally, JPMorgan Chase & Co. cut their price target on shares of Agilent Technologies from $165.00 to $155.00 and set an “overweight” rating for the company in a report on Thursday, May 30th. One investment analyst has rated the stock with a sell rating, six have assigned a hold rating and nine have given a buy rating to the company’s stock. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average target price of $141.60.

About Agilent Technologies

Agilent Technologies, Inc provides application focused solutions to the life sciences, diagnostics, and applied chemical markets worldwide. The company operates in three segments: Life Sciences and Applied Markets, Diagnostics and Genomics, and Agilent CrossLab. The Life Sciences and Applied Markets segment offers liquid chromatography systems and components; liquid chromatography mass spectrometry systems; gas chromatography systems and components; gas chromatography mass spectrometry systems; inductively coupled plasma mass spectrometry instruments; atomic absorption instruments; microwave plasma-atomic emission spectrometry instruments; inductively coupled plasma optical emission spectrometry instruments; raman spectroscopy; cell analysis plate based assays; flow cytometer; real-time cell analyzer; cell imaging systems; microplate reader; laboratory software; information management and analytics; laboratory automation and robotic systems; dissolution testing; and vacuum pumps, and measurement technologies.